Abstracts tagged "rheumatoid arthritis (RA) and women’s health"

Abstract Number: 226 • 2018 ACR/ARHP Annual Meeting
Representation of Elderly People and Women in Rheumatoid Arthritis and Osteoarthritis Trials: A Systematic Review and Meta-Analysis Comparing Clinical Trials with Population-Based Studies
Andriko Palmowski¹, Thomas Buttgereit^1,2, Yannick Palmowski³, Sabrina Mai Nielsen^4,5, Maarten Boers⁶, Robin Christensen^4,5 and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ²Department of Dermatology, Venerology and Allergology, Charité – University Medicine Berlin, Berlin, Germany, ³Center for Musculoskeletal Surgery, Charité – University Medicine Berlin, Berlin, Germany, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Epidemiology and Biostatistics, and Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Elderly people (as commonly defined by an age of ≥65 years) and women have been reported to be underrepresented in clinical trials of various…
Abstract Number: 1533 • 2016 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Women with Rheumatoid Arthritis : A Systematic Review and Meta-Analyses
Anne-Lise Gaillard¹, Thomas Barnetche² and Thierry Schaeverbeke³, ¹Rhumatologie, CHU Bordeaux Pellegrin, Bordeaux, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology Department, Bordeaux Hospital, Bordeaux, France
Background/Purpose: Actually better control of rheumatoid arthritis (RA) activity leads to new interrogations and daily questions about pregnancy. Only few studies have studied pregnancy outcomes…
Abstract Number: 2921 • 2014 ACR/ARHP Annual Meeting
Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis
Sonia Khatter¹, Mark C. Parish², Marie L. Feser², Jason R. Kolfenbach², Ryan W. Gan³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁶, Richard M. Keating⁷, Peter K. Gregersen⁸, Jane H. Buckner⁹, V. Michael Holers¹⁰, Kevin D. Deane², Jill M. Norris³ and M. Kristen Demoruelle², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Epidemiology, Colorado School of Public Health, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Scripps Clinic, La Jolla, CA, ⁸Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: The preclinical period of rheumatoid arthritis (RA) development is characterized by elevations of serum RA-related autoantibodies (Abs) including Abs to citrullinated protein antigens (ACPA)…
Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting
The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Mehret Birru Talabi¹, Rachel Mackey², Larry W. Moreland³, Jan Dorman⁴, Kevin D. Deane⁵, Jeremy Sokolove⁶, V. Michael Holers⁷, William H. Robinson⁸, Brian Wallitt⁹ and Lewis Kuller¹⁰, ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Washington Hospital Center, Baltimore, MD, ¹⁰Epidemiology, University of Pittsburgh, Pittsburgh, PA
Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].